Compare International Business Machines Corp (IBM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs State Street SPDR S&P Biotech ETF — how do they compare? International Business Machines Corp trades at $235.41 (market cap $224.62B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: International Business Machines Corp pays a 2.84% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, International Business Machines Corp nearer its low. Which is the better fit depends on your goals.
| IBM | XBI | |
|---|---|---|
Market Cap | $224.62B | — |
Volume | 4,481,527 | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $329.23 | $164.28 |
52-Week Low | $205.77 | $86.92 |
Enterprise Value | $281.76B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $234.91, down 0.59% today, with a mixed technical outlook showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. The company secured a $240 million AI deal with Together AI, boosting sentiment, but faces a securities fraud investigation following a 25% stock drop. Fundamentals are solid with revenue growth to $67.54 billion in 2025 and a net income margin of 15.52%, though cash flow turned negative.
Outlook is cautiously optimistic with a consensus price target of $257.38, implying 9.6% upside, supported by AI and cloud growth. Risks include the ongoing fraud probe, competitive pressures, and high debt levels. Investors should weigh strong profitability against legal and execution uncertainties in a volatile market.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
